Paul E. Oberstein, MD

Paul E. Oberstein, MD, is an associate professor in the Department of Medicine at New York University (NYU) Grossman School of Medicine; service chief of the Gastrointestinal Medical Oncology Program; and assistant director of the Pancreatic Cancer Center at NYU Langone Health’s Perlmutter Cancer Center

Articles

Aligning Goals in mPDAC: Shared Decision-Making in First-Line Therapy

July 9th 2025

Panelists discuss how patient choice and long-term toxicity considerations, particularly neuropathy differences between NALIRIFOX and FOLFIRINOX, influence treatment decisions while managing patient expectations about stable disease being a positive outcome.

mPDAC: Historical Milestones and Selecting the Right First-Line Regimen

July 9th 2025

Panelists discuss how the evolution of pancreatic cancer treatment has progressed since 2011 with key trials like PRODIGE-4 (FOLFIRINOX) and NAPOLI-3 (NALIRIFOX), and how clinicians choose between regimens based on patient characteristics and adverse effect profiles.

Locally Advanced Pancreatic Cancer: Treatment Approaches and Regimen Selection

June 30th 2025

Panelists discuss how treatment decisions for locally advanced pancreatic cancer should consider systemic therapy followed by radiation, with triplet regimens preferred for younger patients with good performance status, while acknowledging the limited evidence base requiring extrapolation from metastatic data.

Expert Perspectives: 55-Year-Old Woman Presenting With Locally Advanced Pancreatic Cancer: Next Steps

June 30th 2025

Panelists discuss how to approach a 55-year-old woman with locally advanced pancreatic cancer involving portal vein invasion, emphasizing the importance of staging, performance status assessment, and systemic chemotherapy as first-line treatment.

Dr Oberstein on Clinical Applications for Oncodetect in MRD Detection in Solid Tumors

April 24th 2025

Paul E. Oberstein, MD, discusses the clinical applications of the Oncodetect test for molecular residual disease detection in patients with solid tumors.

Dr Oberstein on Data for Pamrevlumab Plus Nab-Paclitaxel/Gemcitabine in PDAC

January 28th 2025

Paul E. Oberstein, MD, discusses the efficacy and safety of pamrevlumab plus chemotherapy in first- and second-line PDAC.

Dr. Oberstein on Remaining Challenges in Metastatic CRC

May 17th 2022

Paul E. Oberstein, MD, discusses remaining challenges in metastatic colorectal cancer.

Dr. Oberstein on the CheckMate 9X8 Trial in Metastatic CRC

May 17th 2022

Paul E. Oberstein, MD, discusses the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer.

Dr. Oberstein on the Utilization of CtDNA in Metastatic CRC

April 18th 2022

Paul E. Oberstein, MD, discusses the utilization of ctDNA in metastatic colorectal cancer.

Dr. Oberstein on the Current Treatment Landscape of CRC

April 13th 2022

Paul E. Oberstein, MD, discusses the current treatment landscape of colorectal cancer.

Dr. Oberstein on PEGPH20 in Patients With Pancreatic Cancer

May 3rd 2018

Paul E. Oberstein, MD, assistant professor of medicine, assistant director, Pancreatic Cancer Center, director, Gastrointestinal Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the use of PEGPH20 in advanced pancreatic cancer.

x